"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
“探索 SYK 抑制剂使卵巢癌对紫杉醇抗肿瘤作用敏感的潜力”
基本信息
- 批准号:10222607
- 负责人:
- 金额:$ 25.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-18 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesBasophilsBiochemicalBiological AssayBiological MarkersBiological ProcessBloodCancer PatientCarboplatinCarcinomaChemoresistanceClinicalClinical ManagementClinical ResearchClinical TrialsCombined Modality TherapyCorrelative StudyDoseDrug resistanceExhibitsFutureGenerationsGoalsHematologic NeoplasmsImmunohistochemistryImmunoprecipitationImplantIn VitroJournalsMalignant neoplasm of ovaryMaximum Tolerated DoseMeasurableMeasuresMethodsMicrotubule StabilizationMicrotubule-Associated ProteinsMicrotubulesMonitorMusOralOutcomeOvarianPaclitaxelPathogenesisPatientsPhasePhase 1/1b Clinical TrialPhosphorylated PeptidePhosphorylationPhysiologicalPlatinumPositioning AttributePreclinical TestingProcessProdrugsProteinsProteomePublic HealthPublishingRecurrenceRecurrent diseaseReportingResistanceRheumatoid ArthritisRoleSYK geneSerousSignal TransductionSiteTestingTimeTissuesToxic effectTreatment outcomeTubulinTumor DebulkingTumor TissueTyrosine Kinase InhibitorTyrosine PhosphorylationVinorelbineWomanXenograft Modelantitumor effectbasebiomarker validationcancer cellcancer therapychemotherapyclinical practiceclinical translationclinically relevantcytotoxicdocetaxelimprovedin vivoinsightintraperitonealmouse modelneoplastic cellnovelnovel therapeutic interventionnovel therapeuticsoverexpressionpatient derived xenograft modelpersonalized approachphase I trialphosphoproteomicspre-clinicalpreclinical efficacypreclinical studypredictive markerresponsesmall moleculesmall molecule inhibitortaxanetherapeutic targettooltranslational studytreatment comparisontreatment responsetumortumor growthtumor xenograft
项目摘要
PROJECT 4: SUMMARY/ ABSTRACT
The purpose of this proposal is to provide critical pre-clinical and early phase clinical evidence to determine
whether the Spleen Tyrosine Kinase (SYK) is a promising therapeutic target in ovarian cancer. We have
previously compared the proteomes of primary and recurrent/post-chemotherapy ovarian high-grade serous
carcinoma (HGSC) tissues from the same patients. Among the preferentially expressed proteins in recurrent
HGSCs, a non-receptor tyrosine kinase, SYK, was prioritized for study because small molecule inhibitors of
SYK including fostamatinib are available for pre-clinical testing and clinical trials. We were able to validate
overexpression of SYK and its active (auto)phosphorylated form in recurrent HGSC after carboplatin and
paclitaxel treatment compared to treatment naive tumors. SYK inhibition exhibited a synergistic cytotoxic effect
with paclitaxel, docetaxel, and vinorelbine, all of which target the microtubule network. Paclitaxel resistant
ovarian cancer cells exhibit higher levels of SYK expression than their carboplatin-resistant counterparts. Our
preliminary phosphoproteomic analysis revealed tubulins and several microtubule-associated proteins as SYK
substrates in ovarian cancer cells. Phosphorylation of these proteins has been shown to increase microtubule
dynamics, a process antagonizing the microtubule-stabilizing effect of paclitaxel. In a mouse tumor xenograft
model, the combination of R406 (the active form of fostamatinib) and paclitaxel significantly suppressed tumor
growth without overt signs of toxicity. Our pre-clinical studies support a novel hypothesis that SYK activity is
required for paclitaxel resistance and that SYK inhibition sensitizes HGSC to the cytotoxic effect of paclitaxel.
Therefore, SYK inhibitors represent a promising new strategy to treat ovarian cancer. To test the above
hypotheses, we propose the following Specific Aims:
Aim 1. Phase I/Ib clinical trial of combined Fostamatinib and paclitaxel in ovarian cancer.
Aim 2. Characterize the prioritized SYK substrates discovered in ovarian cancer cells.
Aim 3. Assess the efficacy of SYK-based combination therapy in mouse models..
项目4:总结/摘要
本提案的目的是提供关键的临床前和早期临床证据,以确定
脾酪氨酸激酶(SYK)是否是卵巢癌有希望的治疗靶点。我们有
先前比较了原发性和复发性/化疗后卵巢高级别浆液性卵巢癌的蛋白质组,
癌(HGSC)组织。在复发性乳腺癌中的优先表达蛋白中,
HGSC,一种非受体酪氨酸激酶,SYK,被优先用于研究,因为小分子抑制剂,
SYK包括fostamatinib可用于临床前测试和临床试验。我们能够验证
卡铂后复发性HGSC中SYK及其活性(自身)磷酸化形式的过表达,
紫杉醇治疗与未经治疗的肿瘤相比。SYK抑制表现出协同细胞毒效应
紫杉醇、多西他赛和长春瑞滨,所有这些都靶向微管网络。紫杉醇耐受性
卵巢癌细胞表现出比卡铂抗性对应物更高水平的SYK表达。我们
初步的磷酸化蛋白质组学分析显示微管蛋白和几种微管相关蛋白,如SYK
卵巢癌细胞中的底物。这些蛋白质的磷酸化已被证明可以增加微管
动力学,拮抗紫杉醇的微管稳定作用的过程。在小鼠肿瘤异种移植物中
在模型中,R406(福他替尼的活性形式)和紫杉醇的组合显著抑制肿瘤
没有明显毒性迹象的生长。我们的临床前研究支持一个新的假设,即SYK活性是
紫杉醇耐药性所需的SYK抑制剂,并且SYK抑制剂使HGSC对紫杉醇的细胞毒性作用敏感。
因此,SYK抑制剂代表了治疗卵巢癌的有希望的新策略。为了测试上述内容,
根据这些假设,我们提出以下具体目标:
目标1。联合福他替尼和紫杉醇治疗卵巢癌的I/Ib期临床试验。
目标二。表征卵巢癌细胞中发现的优先SYK底物。
目标3.评估基于SYK的联合治疗在小鼠模型中的疗效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IE-MING SHIH其他文献
IE-MING SHIH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IE-MING SHIH', 18)}}的其他基金
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach
用于卵巢癌早期检测的多学科 BCC:通过设计方法将发现转化为临床应用
- 批准号:
10673186 - 财政年份:2022
- 资助金额:
$ 25.61万 - 项目类别:
Role of cancer-associated mutations in endometriosis
癌症相关突变在子宫内膜异位症中的作用
- 批准号:
10626987 - 财政年份:2019
- 资助金额:
$ 25.61万 - 项目类别:
Role of cancer-associated mutations in endometriosis
癌症相关突变在子宫内膜异位症中的作用
- 批准号:
9979935 - 财政年份:2019
- 资助金额:
$ 25.61万 - 项目类别:
Role of cancer-associated mutations in endometriosis
癌症相关突变在子宫内膜异位症中的作用
- 批准号:
10381500 - 财政年份:2019
- 资助金额:
$ 25.61万 - 项目类别:
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
“探索 SYK 抑制剂使卵巢癌对紫杉醇抗肿瘤作用敏感的潜力”
- 批准号:
10478850 - 财政年份:2018
- 资助金额:
$ 25.61万 - 项目类别:
相似海外基金
Elucidate the Feature of IgE and Basophils in Atopic Dermatitis
阐明特应性皮炎中 IgE 和嗜碱性粒细胞的特征
- 批准号:
23K15268 - 财政年份:2023
- 资助金额:
$ 25.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The regulatory roles of basophils in skin allergic inflammation by using single-cell RNA-seq analysis
利用单细胞 RNA-seq 分析嗜碱性粒细胞在皮肤过敏性炎症中的调节作用
- 批准号:
22K07115 - 财政年份:2022
- 资助金额:
$ 25.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of basophils and interstitial macrophages in COPD
嗜碱性粒细胞和间质巨噬细胞在 COPD 中的作用
- 批准号:
21K16137 - 财政年份:2021
- 资助金额:
$ 25.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Regulation of Syk Expression in Human Basophils
人嗜碱性粒细胞中 Syk 表达的调节
- 批准号:
10434940 - 财政年份:2021
- 资助金额:
$ 25.61万 - 项目类别:
Regulation of Syk Expression in Human Basophils
人嗜碱性粒细胞中 Syk 表达的调节
- 批准号:
10633098 - 财政年份:2021
- 资助金额:
$ 25.61万 - 项目类别:
Regulation of Syk Expression in Human Basophils
人嗜碱性粒细胞中 Syk 表达的调节
- 批准号:
10276240 - 财政年份:2021
- 资助金额:
$ 25.61万 - 项目类别:
Pathophysiological elucidation of urticaria targeting basophils and its application to drug discovery
针对嗜碱性粒细胞的荨麻疹的病理生理学阐明及其在药物发现中的应用
- 批准号:
20K08651 - 财政年份:2020
- 资助金额:
$ 25.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of mechanisms of itching mediated by basophils in atopic dermatitis and application to clinical treatment
特应性皮炎嗜碱性粒细胞介导的瘙痒机制的阐明及其在临床治疗中的应用
- 批准号:
20K07081 - 财政年份:2020
- 资助金额:
$ 25.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of IL-33 receptor-expressing basophils in the pathogenesis of rheumatoid arthritis
表达IL-33受体的嗜碱性粒细胞在类风湿性关节炎发病机制中的作用
- 批准号:
19K08910 - 财政年份:2019
- 资助金额:
$ 25.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Recruitment, activation and effector pathways of basophils in chronic allograft remodeling
慢性同种异体移植重塑中嗜碱性粒细胞的募集、激活和效应途径
- 批准号:
409355366 - 财政年份:2019
- 资助金额:
$ 25.61万 - 项目类别:
Research Grants